Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
OABI
SELLOmniAb, Inc. · Healthcare · United States · $294M · Avg Vol: $1M/d
COMPANY DESCRIPTION
OmniAb, Inc. is a biotechnology company focused on providing a comprehensive suite of proprietary antibody discovery technologies, including genetically engineered animals and in vitro display systems. These platforms enable its partners to discover and develop novel therapeutic antibodies for a wide range of diseases. OmniAb holds a strong niche market position as a technology licensor, critical to the R&D efforts of numerous pharmaceutical and biotech companies globally.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 59.1M | 34.2M | 26.4M | 18.7M | -31.9% | 28.9M | 30.8M | 46.1M | 57.2% |
| EPS | -0.26 | -0.51 | -0.61 | -0.57 | — | -0.45 | -0.42 | -0.32 | — |
| Shares | 115.2M | 116.9M | 121.6M | 144.3M | +25.2% | 145.0M | — | — | — |
| Debt | 25.8M | 25.6M | 23.2M | 20.3M | -7.6% | 19.7M | — | — | — |
| Equity | 341.4M | 314.6M | 287.6M | 267.0M | -7.9% | — | — | — | — |
| Op CF | -3.6M | 2.3M | -39.7M | -36.5M | — | -25.5M | — | — | — |
| Inv CF | -73.3M | -18.4M | 37.9M | 6.5M | — | — | — | — | — |
| Fin CF | 110.7M | -0.9M | 13.0M | 27.9M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of OABI are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| OABI | OmniAb, Inc.(you) | $294M | 32 | SELL |
| ALXO | ALX Oncology Holdings Inc. | $273M | 31 | SELL |
| ELDN | Eledon Pharmaceuticals, Inc. | $276M | 33 | SELL |
| ZNTL | Zentalis Pharmaceuticals, Inc. | $308M | 28 | SELL |
| PALI | Palisade Bio, Inc. | $339M | 29 | SELL |
| XFOR | X4 Pharmaceuticals, Inc. | $363M | 33 | SELL |
| FATE | Fate Therapeutics, Inc. | $281M | 26 | SELL |
| SABS | SAB Biotherapeutics, Inc. | $268M | 27 | SELL |
| VNDA | Vanda Pharmaceuticals Inc. | $312M | 26 | SELL |
| CCCC | C4 Therapeutics, Inc. | $376M | 34 | SELL |
Peer medians: ROE -25.6% · P/E 27.6x · Gross margin 50.5%